New Blood-Based Biomarker Guidelines Simplify Alzheimer’s Diagnosis
A new clinical guideline released by the Alzheimer’s Association has introduced a system for clinicians to choose blood-based biomarkers (BBMs) to aid in the diagnosis of Alzheimer’s disease (AD). The evidence-based guidelines recommend using BBMs with ≥ 90% sensitivity and specificity as a substitute for amyloid PET or cerebrospinal fluid (CSF) biomarker testing. Tests with … Read more